# Early FDG PET in Melanoma

> **NCT02716077** · NA · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 6 (actual)

## Conditions studied

- Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

## Interventions

- **RADIATION:** FDG PET/CT imaging

## Key facts

- **NCT ID:** NCT02716077
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** low recruitment due to changing treatment landscape for subject population
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716077, "Early FDG PET in Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02716077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*